Gynecologic Oncology

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

The FDA has approved pembrolizumab plus paclitaxel with/without bevacizumab for PD-L1–positive platinum-resistant ovarian cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Dana M. Chase, MD, Robert Neff, MD, and Maurie Markman, MD, comment on the current state of HPV vaccination and screening during cervical cancer awareness month.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

Drs Matulonis and Porter discuss the role of immunotherapy in gynecologic cancer management, focusing on clinical breakthroughs and future directions.

Maurie Markman, MD, discusses the essential yet often complex role associated with interpreting numbers and measurements in oncology.

Interim phase 2 data show nab-sirolimus plus letrozole produced an ORR of 41% and 13.6-month PFS with manageable safety in endometrioid endometrial cancer.

Ten-year data from the PORTEC-3 trial show that adjuvant chemoradiotherapy improves OS and RFS vs radiotherapy alone in high-risk endometrial cancer.

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Vicky Makker, MD, discusses the DESTINY-Endometrial01 trial of T-DXd plus rilvegostomig or pembrolizumab in HER2+ pMMR endometrial cancer.

OncLive has launched a new podcast series, From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD.

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

WES-aneuploidy scores may identify patients with dMMR endometrial cancer who do not benefit from the addition of immunotherapy to chemotherapy.

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.

The addition of atezolizumab to chemotherapy demonstrated noninferior survival vs chemotherapy alone in advanced or recurrent endometrial cancer.

Toripalimab plus CCRT produced a 100% ORR in locally advanced cervical cancer, although the regimen was associated with radiation-related AEs and irAEs.

Chemoradiotherapy improved survival vs radiotherapy alone in the adjuvant setting in high-risk endometrial cancer, particularly in p53-abnormal disease.